A Financial Comparison between Biogen and Corixa

Alex G.

Order the writing of a tailor-made Finance Market study

Free quote online

Market study Format .doc

A Financial Comparison between Biogen and Corixa

Download

Read an extract

Reader
Abstract
Contents
Extract

Abstract

Based on the ratios in Appendix A, it seems that Biogen does not have a high profitability. The values of the ROE, ROA, and Earnings per Share ratios are all negative, and the Profit Margin ratio is only 1.2884%; however, when compared to its competitor, Corixa Corporation, these numbers dominate. It is a trend of the industry to produce low ratios. Biogen has a wider variety of products than its competitor, Corixa. Most of the medications that they have are being tested and are not yet for sale, as with Corixa, but Biogen clearly has a wider variety of products on the market. This is quite an advantage considering that it takes a long time for new drugs to enter the market. The cash flows from operating activities amounts to $267,077 while the net income was only $199,148. The difference between these two numbers is $67,929. This indicates that Biogen is gaining a substantial amount of money from other operating activities besides those that lead to an increase in net income. This indicates that they operate efficiently.

Introduction
Biogen: Meeting current obligations
A proxy statement
The board of directors
Conclusion

Get this table of contents for free after login.

Extract

[...] Mullen, the Chairman, President, and CEO of the company, received a salary of $810,000 with a bonus of $800,000 over the 2002 fiscal year, making his total compensation $1,610,000. The previous year, his total compensation (salary plus bonus) amounted to $1,757,998- this indicates a decrease of from the previous year. This company seems like a safe investment opportunity. First of all, in the field of medicine, there are constantly breakthroughs and new discoveries that revolutionize the field. This company will continue to profit from such discoveries. [...]

[...] A Financial Comparison between Biogen and Corixa Based on the ratios in Appendix it seems that Biogen does not have a high profitability. The values of the ROE, ROA, and Earnings per Share ratios are all negative, and the Profit Margin ratio is only 1.2884 however, when compared to its competitor, Corixa Corporation, these numbers dominate. It is a trend of the industry to produce low ratios. Biogen has a wider variety of products than its competitor, Corixa. Most of the medications that they have are being tested and are not yet for sale, as with Corixa, but Biogen clearly has a wider variety of products on the market. [...]

doc